Our Philosophy
For a better standard of beauty,
QHBIO brings advanced technology and natural harmony together.
QHBIO develops refined medical aesthetic solutions based on advanced technology,
uncompromising quality, and a deep understanding of individual beauty.
Through continuous research, precise manufacturing, and insight into the needs of global markets,
we provide reliable products for medical professionals and partners while helping people discover
their
own authentic beauty and experience greater confidence in their everyday lives.
QHBIO Collection
From volume and contour to hydration and skin refinement,
QHBIO’s diverse brand portfolio provides specialized aesthetic solutions
designed to meet the evolving needs of medical professionals and global markets.
Refined Volume, Naturally Defined
WELLSTOX is designed with advanced hyaluronic acid technology to deliver smooth injection,
precise contouring, and naturally balanced volume, helping create refined aesthetic
results that enhance each individual’s unique features with harmony and confidence.
Naturally Sculpted, Beautifully Defined
ARTLINE is a high-capacity hyaluronic acid body filler developed to create natural-looking volume
and refined body contours, combining strong viscoelasticity, reliable structural support,
and long-lasting shape retention for balanced aesthetic results.
Powerful Lift, Naturally Refined
TIRAMER combines advanced hyaluronic acid filler technology and premium lifting threads to deliver
natural-looking volume, strong lifting performance, and precise contour definition while
supporting
a smooth and comfortable treatment experience.
Revitalize Deeply, Glow Naturally
AMORUCCI combines high-purity hyaluronic acid, PDRN, active nutrients,
and advanced collagen technology to deeply hydrate and revitalize the skin, helping improve
elasticity,
texture, fine lines, and natural radiance without creating artificial-looking volume.
QHBIO PR·Press
News
Yonsei Midain Clinic (CEO and Head Doctor Kim Ji-hyun) announced that it has introduced WELLSTOX AQUA PRO LIDOCAINE, a hyaluronic acid (HA)-based medical device, and plans to use it for customized aesthetic treatments tailored to each patient’s facial condition.
WELLSTOX AQUA PRO LIDOCAINE is a monophasic hyaluronic acid injectable. Its HA is cross-linked with DVS (Divinyl Sulfone) and designed with uniform density throughout. Featuring a homogeneous formulation and containing lidocaine, it is indicated for the temporary improvement of facial wrinkles in adults through physical restoration.
“In aesthetic medicine, interest is growing in treatments that go beyond improving wrinkles or volume in a specific area to consider skin condition and the harmony of the face as a whole,” said Dr. Kim. “As patients present with a range of concerns, such as dry skin, fine lines and loss of elasticity, it is becoming more important to assess each individual’s condition in detail and choose the right treatment approach.”
“Treatments with hyaluronic acid injectables require an understanding of the product’s characteristics, as well as consideration of each patient’s skin thickness, tissue condition and facial movement,” she added. “Setting the appropriate injection points and volume, and taking a careful approach so that the product distributes evenly across the treated area, are key to achieving natural facial improvement.”
With the introduction of WELLSTOX AQUA PRO, Dr. Kim said the clinic plans to further refine its treatment plans according to each patient’s facial wrinkles and skin condition, alongside its existing skin aesthetic treatments. Drawing on the medical team’s clinical experience and the product’s characteristics, the clinic will continue to offer hair-related care and customized aesthetic skin services.
News
Jeollabuk-do (Jeonbuk State) is targeting the global market by joining nine local biotech companies — including QHBIO — at BIO KOREA 2026, held April 28–30 at COEX.
Through a dedicated "Jeonbuk Pavilion," QHBIO and fellow participants (Hamsoa Pharm, Basgenbio, Biorhealogics, Namusum, Jefit, Youth Bio Global, Juyoung Bio, and Airlab) will showcase technologies spanning medical devices, functional foods, regenerative medicine, and AI-based drug discovery, alongside on-site technical consultations and partner matchmaking.
The pavilion will also host a project planning meeting with KIST Europe to expand participation in the EU's Horizon Europe program, building on the Jeonbuk Biotech Cooperation Center established within KIST Europe in October 2024.
Cho Sung-yeon, Director of Jeollabuk-do's Bio-Defense Industry Division, called the exhibition an important opportunity to showcase Jeonbuk biotech companies' — including QHBIO's — technological competitiveness to the global market.
News
The Korea International Trade Association held its 60th Trade Day commemorative ceremony on the 5th at COEX in Samseong-dong, with approximately 1,200 attendees including trade contributors and heads of government and affiliated organizations.
The list of Export Tower award recipients by export value is as follows.
The Export Tower is awarded based on export performance from July 1 of the previous year through June 30 of this year. This year, 1,704 companies received the Export Tower for achieving export performance of at least USD 1 million.
$5 Million Tower: QHBIO — CEO Lee Hae-kyung
